Cargando…

A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines

Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kendric, Shrestha, Raunak, Wyatt, Alexander W., Reddy, Anupama, Lehár, Joseph, Wang, Yuzhou, Lapuk, Anna, Collins, Colin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103868/
https://www.ncbi.nlm.nih.gov/pubmed/25036042
http://dx.doi.org/10.1371/journal.pone.0103050
_version_ 1782327209505062912
author Wang, Kendric
Shrestha, Raunak
Wyatt, Alexander W.
Reddy, Anupama
Lehár, Joseph
Wang, Yuzhou
Lapuk, Anna
Collins, Colin C.
author_facet Wang, Kendric
Shrestha, Raunak
Wyatt, Alexander W.
Reddy, Anupama
Lehár, Joseph
Wang, Yuzhou
Lapuk, Anna
Collins, Colin C.
author_sort Wang, Kendric
collection PubMed
description Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alterations of drug targets. However, these alterations are sufficient to explain only a minority of the population, and additional mechanisms of drug resistance or sensitivity are required to explain the remaining spectrum of patient responses to ultimately achieve the goal of precision oncology. We hypothesized that a pan-cancer analysis of in vitro drug sensitivities across numerous cancer lineages will improve the detection of statistical associations and yield more robust and, importantly, recurrent determinants of response. In this study, we developed a statistical framework based on the meta-analysis of expression profiles to identify pan-cancer markers and mechanisms of drug response. Using the Cancer Cell Line Encyclopaedia (CCLE), a large panel of several hundred cancer cell lines from numerous distinct lineages, we characterized both known and novel mechanisms of response to cytotoxic drugs including inhibitors of Topoisomerase 1 (TOP1; Topotecan, Irinotecan) and targeted therapies including inhibitors of histone deacetylases (HDAC; Panobinostat) and MAP/ERK kinases (MEK; PD-0325901, AZD6244). Notably, our analysis implicated reduced replication and transcriptional rates, as well as deficiency in DNA damage repair genes in resistance to TOP1 inhibitors. The constitutive activation of several signaling pathways including the interferon/STAT-1 pathway was implicated in resistance to the pan-HDAC inhibitor. Finally, a number of dysregulations upstream of MEK were identified as compensatory mechanisms of resistance to the MEK inhibitors. In comparison to alternative pan-cancer analysis strategies, our approach can better elucidate relevant drug response mechanisms. Moreover, the compendium of putative markers and mechanisms identified through our analysis can serve as a foundation for future studies into these drugs.
format Online
Article
Text
id pubmed-4103868
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41038682014-07-21 A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines Wang, Kendric Shrestha, Raunak Wyatt, Alexander W. Reddy, Anupama Lehár, Joseph Wang, Yuzhou Lapuk, Anna Collins, Colin C. PLoS One Research Article Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alterations of drug targets. However, these alterations are sufficient to explain only a minority of the population, and additional mechanisms of drug resistance or sensitivity are required to explain the remaining spectrum of patient responses to ultimately achieve the goal of precision oncology. We hypothesized that a pan-cancer analysis of in vitro drug sensitivities across numerous cancer lineages will improve the detection of statistical associations and yield more robust and, importantly, recurrent determinants of response. In this study, we developed a statistical framework based on the meta-analysis of expression profiles to identify pan-cancer markers and mechanisms of drug response. Using the Cancer Cell Line Encyclopaedia (CCLE), a large panel of several hundred cancer cell lines from numerous distinct lineages, we characterized both known and novel mechanisms of response to cytotoxic drugs including inhibitors of Topoisomerase 1 (TOP1; Topotecan, Irinotecan) and targeted therapies including inhibitors of histone deacetylases (HDAC; Panobinostat) and MAP/ERK kinases (MEK; PD-0325901, AZD6244). Notably, our analysis implicated reduced replication and transcriptional rates, as well as deficiency in DNA damage repair genes in resistance to TOP1 inhibitors. The constitutive activation of several signaling pathways including the interferon/STAT-1 pathway was implicated in resistance to the pan-HDAC inhibitor. Finally, a number of dysregulations upstream of MEK were identified as compensatory mechanisms of resistance to the MEK inhibitors. In comparison to alternative pan-cancer analysis strategies, our approach can better elucidate relevant drug response mechanisms. Moreover, the compendium of putative markers and mechanisms identified through our analysis can serve as a foundation for future studies into these drugs. Public Library of Science 2014-07-18 /pmc/articles/PMC4103868/ /pubmed/25036042 http://dx.doi.org/10.1371/journal.pone.0103050 Text en © 2014 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wang, Kendric
Shrestha, Raunak
Wyatt, Alexander W.
Reddy, Anupama
Lehár, Joseph
Wang, Yuzhou
Lapuk, Anna
Collins, Colin C.
A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
title A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
title_full A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
title_fullStr A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
title_full_unstemmed A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
title_short A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
title_sort meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103868/
https://www.ncbi.nlm.nih.gov/pubmed/25036042
http://dx.doi.org/10.1371/journal.pone.0103050
work_keys_str_mv AT wangkendric ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT shrestharaunak ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT wyattalexanderw ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT reddyanupama ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT leharjoseph ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT wangyuzhou ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT lapukanna ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT collinscolinc ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT wangkendric metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT shrestharaunak metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT wyattalexanderw metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT reddyanupama metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT leharjoseph metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT wangyuzhou metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT lapukanna metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines
AT collinscolinc metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines